ALLO (Allogene Therapeutics) EPS (Basic) : $-1.33 (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Allogene Therapeutics EPS (Basic)?

Allogene Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was $-0.28. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.33.

Allogene Therapeutics's EPS (Diluted) for the three months ended in Dec. 2024 was $-0.28. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.33.

Allogene Therapeutics's EPS without NRI for the three months ended in Dec. 2024 was $-0.28. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -1.25.

During the past 3 years, the average EPS without NRI Growth Rate was 2.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Allogene Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 43.20% per year. The lowest was -9.20% per year. And the median was 5.35% per year.

Allogene Therapeutics EPS (Basic) Historical Data

The historical data trend for Allogene Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allogene Therapeutics EPS (Basic) Chart

Allogene Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-2.63

-1.34

-2.38

-2.09

-1.32

Allogene Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															-0.51	-0.38	-0.35	-0.32	-0.28

Allogene Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Allogene Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-257.59	-	0)	/	194.812
	=	-1.32

Allogene Therapeutics's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-59.939	-	0)	/	210.687
	=	-0.28

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.33

Allogene Therapeutics (NAS:ALLO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Allogene Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Allogene Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Allogene Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allogene Therapeutics Inc (NAS:ALLO) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

210 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.allogene.com

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Executives

David D Chang	director, officer: President and CEO	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Deborah M. Messemer	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Earl Martin Douglas	officer: GENERAL COUNSEL	BIOMIMETIC THERAPEUTICS, INC., 389 NICHOL MILL LANE, FRANKLIN TN 37067
Zachary Roberts	officer: EVP of R&D	C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Geoffrey M. Parker	officer: CHIEF FINANCIAL OFFICER	15 RIORDAN PLACE, MENLO PARK CA 94025
Timothy L. Moore	officer: Chief Technical Officer	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Franz B Humer	director	388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
Arie Belldegrun	director, 10 percent owner	UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Yinlin Jack Chen	officer: SVP, Finance	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Stephen Mayo	director	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Lillian Smith	officer: VP, Corporate Counsel	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Veer Bhavnagri	officer: General Counsel	C/O ALLOGENE THERAPEUTICS, INC., 210 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Owen N. Witte	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rafael Amado	officer: EVP of R&D and CMO	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Alison Moore	officer: Chief Technical Officer	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080